Findings from this systematic review revealed several knowledge gaps that would preclude the conduct of a robust assessment of the benefits and outcomes associated with a disease-modifying FA therapy. Additional understanding regarding patient and caregiver HRQoL and costs is required.
Saturday, August 20, 2022
A systematic review of disease prevalence, health-related quality of life, and economic outcomes associated with Friedreich’s Ataxia
Katherine Buesch & Rongrong Zhang (2022) , Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2112870
